ALZI
ALZAI signed a non-binding MOU with Quanterix to explore Alzheimer's diagnostics collaboration.
ALZAI joins AABC, signalling intent but offering no immediate commercial or financial impact.
Alzai Health commits US$425,000 to a four-month digital marketing campaign, pending TSXV approval.
ALZAI Health Corp. begins trading on the OTCQB, expanding access for U.S. investors.
Alzai is spending US$425,000 on a year-long digital marketing campaign.
ALZAI signed a non-binding MOU with Linus Health; no financials or deals disclosed.
ALZAI’s licensing deal is all promise, no proof—investors get hype, not hard numbers.
Technical validation is real, but commercial and financial impact remains entirely unproven.
Big promises, little proof—investors face long odds and longer timelines here.